EUVIMED · CrossrefZeitschrift
Molecular Cancer Therapeutics
ISSN 1535-7163 · American Association for Cancer Research (AACR)
Neueste Artikel
Combined ATR and Mitotic Inhibition Is Effective against MYCN -Amplified Neuroblastoma
Nanoparticle Codelivery of Microtubule Inhibitors and Cisplatin Overcomes DNA Repair–Mediated Resistance in Head and Neck Cancer
Systematic Evaluation of Combination Strategies with Rezatapopt in p53 Y220C-Mutant Cancer Models
Variant-Selective and Pan-RAS Inhibitors Enhance Targeted Agent Activity in Patient-Derived Multi–cell-type Tumor Spheroids
Synthetic Inducible Bacteria Normalize the Microenvironment of Refractory Tumors, Potentiating Checkpoint Inhibitor Responses
Tri-Specific Humabody CB307 Targeting CD137, Prostate-Specific Membrane Antigen, and Human Serum Albumin Whole-Body Biodistribution Measured with 89Zr-CB307 PET
Dual Inhibition of PARP and ATR Induces Synthetic Lethal Vulnerability in Prostate Cancer with CDK12 Deficiency
GITR and GITR-L RNA Expression Levels Correlate with Better Survival and Response to Immunotherapy
Enhanced Antitumor Efficacy of Combined PTC596 and PD-1 Blockade in Hepatocellular Carcinoma
QW-5-70 Targets the Colchicine Site and Demonstrates Antitumor Activity in P-gp–Overexpressing Cancer Models
Suppression of AKT Activation through LZK Inhibition Limits Tumor Growth in Esophageal and Head and Neck Cancers
BLU-451, a CNS-Active, Potent, and Selective Small-Molecule Inhibitor against Uncommon EGFR Mutations
Selected Articles from This Issue
Mechanisms of Acquired Resistance Following Dual EGFR/MET Inhibition in MET -Amplified EGFR TKI–Resistant Lung Cancer
Potent Anti-Tumor Activity of the AXL-Targeted Antibody-Drug Conjugate, Mipasetamab Uzoptirine (ADCT-601), in Preclinical Models of Adenoid Cystic Carcinoma
H3K9me3 Regulates IFNγlow Tex Cell Differentiation to Promote Colon Tumor Liver Metastasis
Quantification of Antibody–Drug Conjugate Targets in Head and Neck Squamous Cell Carcinoma
Novel antibody-drug conjugates targeting EphA3 in tumours and the tumour microenvironment
Aberrant expression of HERV-K envelope in lymphoma represents an opportunity for novel treatments.
ADCE-T02: A Next-generation Antibody–Drug Conjugate Targeting Tissue Factor Demonstrates Superior Preclinical Efficacy and Tolerability
Therapeutic Targeting of β-Catenin in Cancer
Molecular Design and Preclinical Evaluation of GenSci143, a Novel B7-H3–Directed and PSMA-Directed Bispecific Antibody–Drug Conjugate, for the Treatment of Prostate Cancer
PLK1 Inhibition by Onvansertib Enhances Paclitaxel Efficacy and Overcomes Resistance in HR+/HER2− Breast Cancer Refractory to Endocrine Therapy and CDK4/6 Inhibitors
GD2 Induction by Combination Chromatin-Directed Inhibitors Enhances Targeting of Ewing Sarcoma and Osteosarcoma by CAR T Cells
Proliferating Cell Nuclear Antigen as New Therapeutic Target in Multiple Myeloma
ATR inhibitors and gemcitabine synergize to induce cell death in TP53-mutant, ATRX-wildtype uterine leiomyosarcoma
Dual targeting of DHODH and SLC29A1 overcomes metabolic resistance and enhances antitumor immune responses in PDAC
Preclinical Characterization of ADCT-241, an Exatecan-Based Antibody–Drug Conjugate against PSMA for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Preclinical modeling of trastuzumab deruxtecan in a mouse model of brain metastatic triple-negative breast cancer identifies two contributors to efficacy.
Inhibition of PLK1 Helps Restrict c-Met–Induced Growth and Therapeutic Resistance of Renal Cancer Cells
EUVIMED